316 completed, 106 unknown, 81 recruiting, 34 active not recruiting. 187 Phase 4, 160 Phase 3, 122 Phase 2, 79 Phase 1, 48 Not applicable.
Follow dapagliflozin: new trials by email Literature Review of dapagliflozin trials Research Report on dapagliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin - Type 1 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Not yet recruiting | University Medical Center Groningen | 36 | 2027-01-01 | 2026-10-20 |
| Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis Dapagliflozin, Empagliflozin, Methotrexate - Rheumatoid Arthritis (RA) | Phase 2 | Not yet recruiting | Al-Azhar University | 90 | 2026-12-01 | 2026-10-08 |
| Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis Dapagliflozin (DAPA), Spironolactone (drug), Spironolactone + Dapagliflozin - Aortic Stenosis | Phase 2 | Not yet recruiting | University College, London | 445 | 2026-12-01 | 2026-09-11 |
| iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) N0892, Januvia® + Glifage XR® + Placebo, Forxiga® + Glifage XR® + Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-11-30 | 2025-12-18 | |
| Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy Forxiga - Glomerulonephritis | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2026-11-01 | 2026-06-22 |
| Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis Rezdiffra, Resmetirom, ACTOS/pioglitazone - MASH - Metabolic Dysfunction-Associated Steatohepatitis | Phase 4 | Recruiting | Madrigal Pharmaceuticals, Inc. | 150 | 2026-10-07 | 2026-10-16 |
| Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD Metformin + Dapagliflozin, Metformin - Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease | Not applicable | Not yet recruiting | The 95th Hospital of Putian，Putian, Fujian, China | 84 | 2026-10-01 | 2026-08-21 |
| Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome Metformin, Dapagliflozin (10mg Tab) - Poly Cystic Ovary Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 60 | 2026-09-10 | 2026-09-09 |
| A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin - Renal Insufficiency, Chronic | Phase 3 | Recruiting | AstraZeneca | 2800 | 2026-09-01 | 2026-09-24 |
| Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes Dapagliflozin (10mg Tab) - Myelodysplastic Syndromes (MDS), Anemia | Phase 2 | Not yet recruiting | Seug yun Yoon, MD | 37 | 2026-09-01 | 2026-04-08 |
| Dapagliflozin for Long COVID Syndrome Dapagliflozin (DAPA), Placebo - COVID - 19, Long COVID Syndrome | Phase 3 | Not yet recruiting | Ottawa Heart Institute Research Corporation | 192 | 2026-09-01 | 2026-07-01 |
| Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial Dapagliflozin, Metformin, Common Lifestyle Program - Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain | Phase 4 | Not yet recruiting | Sultan Qaboos University | 110 | 2026-09-01 | 2026-06-10 |
| SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial SGLT2i, Placebo - Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors | Phase 2 | Not yet recruiting | Odense University Hospital | 184 | 2026-09-01 | 2026-07-02 |
| aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA) Dapagliflozin (10mg Tab), Placebo ( FE) - Angina With Non-Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction (CMD) | Phase 2 | Not yet recruiting | The Christ Hospital | 120 | 2026-09-01 | 2026-08-03 |
| Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin Balcinrenone/dapagliflozin - Kidney Failure | Phase 1 | Completed | AstraZeneca | 10 | 2026-08-06 | 2026-10-20 |
| DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform Dapagliflozin (10mg Tab), Continuous Glucose Monitoring (CGM), Self-Monitoring of Blood Glucose (SMBG) - Type 2 Diabetes Mellitus (T2DM) | Not applicable | Not yet recruiting | The Third Xiangya Hospital of Central South University | 120 | 2026-08-01 | 2026-05-19 |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo - Type 2 Diabetes Mellitus | Phase 3 | Recruiting | AstraZeneca | 800 | 2026-07-06 | 2026-08-31 |
| A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo - Type 2 Diabetes Mellitus | Phase 3 | Recruiting | AstraZeneca | 2000 | 2026-07-06 | 2026-08-31 |
| The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy - Fontan, Heart Failure | Phase 4 | Recruiting | The University of Hong Kong | 30 | 2026-07-01 | 2026-07-28 |
| "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial" Dapagliflozin - Ascites Hepatic | Phase 2 / Phase 3 | Recruiting | Beni-Suef University | 52 | 2026-07-01 | 2026-07-06 |
Showing 20 of 607. Sign in to see all of them.
Diabetes Mellitus, Type 2 (225) · Diabetes Mellitus (59) · Heart Failure (57) · Renal Insufficiency, Chronic (45) · Diabetes Mellitus, Type 1 (25) · Hypertension (14) · Obesity (12) · Breast Neoplasms (11) · Insulin Resistance (11) · Prediabetic State (11) · Atrial Fibrillation (10) · Diabetic Nephropathies (10) · Hyperglycemia (10) · Kidney Diseases (10) · Myocardial Infarction (10)
AstraZeneca (125) · The University of Texas Health Science Center at San Antonio (12) · Mansoura University (10) · Assiut University (9) · LG Chem (8) · Ain Shams University (7) · Tanta University (6) · University of Guadalajara (6) · Washington University School of Medicine (6) · Beni-Suef University (5) · Boryung Pharmaceutical Co., Ltd (5) · Brigham and Women's Hospital (5) · Dong-A ST Co., Ltd. (5) · Medical University of Vienna (5) · The University of Hong Kong (5)
United States (169) · South Korea (68) · China (62) · Mexico (56) · Egypt (55) · Canada (54) · Germany (50) · United Kingdom (45) · Spain (41) · Poland (40) · Brazil (35) · Italy (35) · Sweden (32) · India (31) · Japan (31)
Mikhail Kosiborod, MD (4) · Eugenio Cersosimo, MD,PhD (3) · Ralph A DeFronzo, MD (3) · Ralph DeFronzo, MD (3) · Anna Maria Langkilde (2) · Anna Maria Langkilde, MD (2) · Bassem Zarif, MD (2) · Hiddo J Lambers Heerspink, PhD, PharmD (2) · Jan Eriksson, MD (2) · Moheb Magdy Mouris, MD (2)
PMID 38770818, PMID 26894924, PMID 31535829, PMID 26378978, PMID 32970396, PMID 27461213, PMID 28605608, PMID 31081589, PMID 33368935, PMID 30415602, PMID 32865377, PMID 35403243, PMID 36027570, PMID 40913594, PMID 19114612, PMID 23668478, PMID 25352655, PMID 25425451, PMID 27440829, PMID 29802530, PMID 30756462, PMID 30990260, PMID 31196815, PMID 31364269, PMID 31843945, PMID 32559474, PMID 32691513, PMID 32877652, PMID 32946821, PMID 34447992, PMID 34473343, PMID 34693515, PMID 35241246, PMID 36189985, PMID 36811901, PMID 36881399, PMID 37170711, PMID 37203441, PMID 37210608, PMID 37211977, PMID 37220172, PMID 37227937, PMID 37886880, PMID 38017482, PMID 38059368, PMID 38299639, PMID 38320525, PMID 38334499, PMID 38430085, PMID 39046727
2023 (13), 2014 (9), 2015 (8), 2016 (6), 2017 (5), 2018 (4), 2025 (4), 2019 (3), R01DK024092 (3), R01DK107680 (3), 1OT2HL156812-01 (1), K23DK142042 (1), K23HL150236 (1), P30AG044271 (1), P50CA196510 (1)